Evidence map›Paper›PMID 42654116›Full record

ReviewPharmaceutics2026

Nanotechnology in Pediatric Neurology: Applications and Innovations.

Raluca Ioana Teleanu, Ioana Alexandra Lungescu, Adelina-Gabriela Niculescu, Ana Cojocaru, Radu Ștefan Perjoc, Bianca Teodora Chenescu, Eugenia Roza, Oana Aurelia Vladâcenco, Alexandru Mihai Grumezescu, Daniel Mihai Teleanu

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Raluca Ioana Teleanu"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0003-3038-6939
Ioana Alexandra LungescuNational University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania.
Adelina-Gabriela NiculescuNational University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania.ORCID 0000-0001-8968-504X
Ana Cojocaru"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Radu Ștefan Perjoc"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0001-7014-7065
Bianca Teodora Chenescu"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Eugenia Roza"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0002-5061-7821
Oana Aurelia Vladâcenco"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Alexandru Mihai GrumezescuNational University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania.ORCID 0000-0003-3036-094X
Daniel Mihai Teleanu"Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology is rapidly transforming the perspective on pediatric neurology, enabling diagnostic, therapeutic, and monitoring strategies tailored to the unique features of neurological illnesses in children. This review acknowledges the problems caused by delays in diagnosis, the limitations of conventional procedures, and the need for new, focused approaches, highlighting recent advances in nanoscale materials and smart nanocarriers. Specifically, this paper summarizes advances in nanomaterials that can overcome physiological barriers, such as the developing blood-brain barrier (BBB) and age-dependent pharmacokinetics. We discuss innovations in stimuli-responsive delivery systems, theranostic platforms, and multimodal nanohybrids designed for precise targeting and real-time treatment monitoring. Special emphasis is placed on pediatric-specific considerations, including developmental differences in immune and metabolic responses, the necessity for age-adjusted dosing, and the potential long-term safety implications of nanoparticle exposure. Transformative applications are explored in various pediatric neurological conditions, including brain tumors, epilepsy, neurodevelopmental disorders, and rare degenerative diseases, emphasizing both achievements and challenges in translation. This paper evaluates various regulatory, ethical, and societal factors, alongside the integration of converging technologies such as AI-driven nanoparticle optimization, brain organoids, and digital twins to accelerate personalized therapy development. Conclusively, this paper emphasizes the importance of interdisciplinary collaboration, pediatric-focused clinical trial designs, and sustained investment to fully realize the potential of nanotechnology in improving neurological outcomes for children.

Indexed as

AI-driven nanomedicinebrain organoidsclinical translationdigital twinsnanotechnologypediatric brain tumorspediatric neurologypediatric pharmacokineticssmart nanocarrierstheranostics

Identifiers

PMID42654116
PMCPMC13516608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.